Accelerated Approval: Mend, Don't End, Pazdur Tells ODAC After Avastin
Executive Summary
Genentech's Avastin may not have produced a storybook ending in metastatic breast cancer, but it still serves as an example of how the accelerated approval process can work
You may also be interested in...
FDA Asks ODAC To Ponder Shift Away From Single-Arm Studies
At its Feb. 8 meeting on issues surrounding confirmatory post-marketing studies, the Oncologic Drugs Advisory Committee will discuss whether and when randomized studies should be required to secure accelerated approval.
FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less
A Senate Appropriations Committee-approved funding package would provide the Center for Drug Evaluation and Research with $5 million more than requested by the Obama administration
FDA Funding Bill In Senate Gives Generic Drugs More, But Commissioner Less
A Senate Appropriations Committee-approved funding package would provide the Center for Drug Evaluation and Research with $5 million more than requested by the Obama administration